As has been widely acknowledged, one of the most meaningful steps a business can take is to establish a single point of contact that permits one set of communications, with the whole of a client ...

Generative AI (GenAI) technology is already transforming everyday regulatory and safety processes, thanks to its ability to digest, assess, and summarise key insights and findings from across vast ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

The Federal Trade Commission (FTC) has sued the top three pharmacy benefit managers (PBMs) in the US for operating a "perverse drug rebate system" that it claims artificially inflated the prices ...

UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of the year.

In the pharmaceutical research field, the journey from laboratory to pharmacy shelf is fraught with challenges, such as the high failure rates and increasing costs of clinical trials. Significant ...

The month-long standoff between the US Health Resources and Services Administration (HRSA) and Johnson & Johnson came to an end yesterday when J&J officially backed down from its plan to switch to ...

Phase 2 results with Wave Life Sciences' Duchenne muscular dystrophy candidate WVE-N531 pushed the company's share price to its highest level in a year and could lead to discussions with ...

In the third, final, and by most reckonings most inconsequential, national debate of the US presidential election, vice presidential candidates Tim Walz and JD Vance were forceful, unexpectedly ...

Sanofi's Sarclisa has been an also-ran in the anti-CD38 antibody class behind Johnson & Johnson and Genmab's blockbuster Darzalex, but now has a chance to steal some of the spotlight. The FDA has ...

AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator ...

In the study, clesrovimab (MK-1654) significantly reduced the incidence of RSV disease and hospitalisations in healthy ...